Measuring Tissue Sodium With MRI in Primary Aldosteronism
Studies sodium levels in muscle using a scan in adults with primary aldosteronism.
Plain-language title generated from the registry record
Registry title: Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat
Key facts
- Where
- Singapore, SingaporeSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 70 years old?
Source: NCT06569589, who can take part
Where in Singapore
- Changi General HospitalSingapore, SingaporeTaking people
- Duke NUS Medical SchoolSingapore, SingaporeTaking people
- Sengkang General HospitalSingapore, SingaporeNot yet recruiting
- Singapore General HospitalSingapore, SingaporeNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jens Titze
- Trial code
- NCT06569589
- Record updated
- 6 June 2025
- Original description
The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+/K+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. In analogy to the role of HbA1c as a metabolic long-term marker in diabetes, the quantifiable changes in muscle Na+ content may deliver the data evidence necessary to justify and conduct randomized diagnostic endpoint outcome trials in the future, with the ultimate aim to improve PA detection rate and treatment.Read full original descriptionShow less
Tissue Sodium Quantification in Patients With Primary Aldosteronism
The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+/K+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. In analogy to the role of HbA1c as a metabolic long-term marker in diabetes, the quantifiable changes in muscle Na+ content may deliver the data evidence necessary to justify and conduct randomized diagnostic endpoint outcome trials in the future, with the ultimate aim to improve PA detection rate and treatment.
Inclusion: Age 21-70 years, with arterial hypertension or suspected to have primary aldosteronism based on Endocrine Society Guidelines; Male and female patients older than 21 years; Willingness to participate and ability to provide informed consent.
Exclusion: Patients with exclusion criteria for the MRI, such as:; implanted devices (surgical clips, heart pacemakers or defibrillators, cochlear implants); iron-based tattoos; any other pieces of metal or devices that are not MR-Safe anywhere in the body; patients who exhibit noticeable anxiety and/or claustrophobia into the MRI scanner; pregnancy; Diagnosis of heart failure NYHA classes III and IV; Liver disease with cirrhosis (Child-Pugh class C) or hypoalbuminemia; Patients with active cancer or severe comorbid conditions likely to compromise survival or study participation; Impaired renal function with eGFR<30 ml/min or proteinuria > 1 g/24h; Muscular dystrophies; Unwillingness or other inability to cooperate.